Are there atrial selective/predominant targets for "upstream" atrial fibrillation therapy?

Heart Rhythm

Volumn 5, Issue 9, 2008, Pages 1294-1295

  Burashnikov, Alexander ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; CALCINEURIN; CALCIUM; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN GP 130; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LAMBDA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POTASSIUM CHANNEL BLOCKING AGENT; RAC1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM CHANNEL BLOCKING AGENT; STAT PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE;

CALCIUM TRANSPORT; CHANNEL GATING; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; GENE OVEREXPRESSION; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR DENSITY; SIGNAL TRANSDUCTION;

ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CELLULAR STRUCTURES; GTP PHOSPHOHYDROLASES; HUMANS; INFLAMMATION; JANUS KINASE 2; JANUS KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TRANSLOCATION, GENETIC;

EID: 50949124301     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2008.06.007     Document Type: Editorial

References (23)

1. Nattel S., and Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 5 (2006) 1034-1049
2. Burashnikov A., and Antzelevitch C. Atrial-selective sodium channel blockers. Do they exist?. J Cardiovasc Pharmacol (2008) (in press)
3. Goette A., Bukowska A., and Lendeckel U. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Curr Opin Pharmacol 7 (2007) 219-224
4. Savelieva I., and Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 5 (2008) 30-41
5. Nattel S., Burstein B., and Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol 1 (2008) 62-73
6. Lin C.S., and Pan C.H. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65 (2008) 1489-1508
7. Fenelon G., Shepard R.K., and Stambler B.S. Focal origin of atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 14 (2003) 1093-1102
8. Salehian O., Healey J., Stambler B., et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 154 (2007) 448-453
9. 1 transgene in the heart. Circ Res 86 (2000) 571-579
10. Dudley Jr. S.C., Hoch N.E., McCann L.A., et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112 (2005) 1266-1273
11. Burstein B., Libby E., Calderone A., et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117 (2008) 1630-1641
12. Shimano M., Tsuji Y., Inden Y., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 5 (2008) 451-459
13. Tsai C.T., Lai L.P., Kuo K.T., et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 117 (2008) 344-355
14. Hanna N., Cardin S., Leung T.K., et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63 (2004) 236-244
15. Xiao H.D., Fuchs S., Campbell D.J., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165 (2004) 1019-1032
16. Verheule S., Sato T., Everett T., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 94 (2004) 1458-1465
17. Adam O., Frost G., Custodis F., et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 50 (2007) 359-367
18. Touyz R.M., Sventek P., Lariviere R., et al. Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype 1 receptors. Hypertension 27 (1996) 1090-1096
19. Tsai C.-T., Lin J.L., Lai L.P., et al. Membrane translocation of small GTPase Rac1 and activation of STAT1 and STAT3 in pacing-induced sustained atrial fibrillation. Heart Rhythm 5 (2008) 1285-1293
20. Fischer P., and Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol 102 (2007) 393-411
21. Dobrev D., Friedrich A., Voigt N., et al. The G Protein-Gated Potassium Current IK,ACh Is Constitutively Active in Patients With Chronic Atrial Fibrillation. Circulation 112 (2005) 3697-3706
22. Burashnikov A., Di Diego J.M., Zygmunt A.C., et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116 (2007) 1449-1457
23. Burashnikov A., and Antzelevitch C. How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation?. JAFIB 1 (2008) 98-107